更新于：2024-12-12
Sirolimus Albumin-Bound
西罗莫司(白蛋白结合型)
更新于：2024-12-12
概要
基本信息
药物类型 分子胶 |
别名 Nab-Rapamycin、Nab-sirolimus、Sirolimus Albumin-Bound Nanoparticles + [5] |
作用机制 MUT刺激剂(甲基丙二酰辅酶A变位酶刺激剂)、mTOR抑制剂(丝氨酸/苏氨酸蛋白激酶mTOR抑制剂)、免疫抑制剂 |
在研适应症 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2021-11-22), |
最高研发阶段(中国)临床3期 |
特殊审评快速通道 (美国)、孤儿药 (美国) |
登录后查看时间轴
结构
分子式C51H79NO13 |
InChIKeyQFJCIRLUMZQUOT-HPLJOQBZSA-N |
CAS号53123-88-9 |
关联
32
项与 西罗莫司(白蛋白结合型) 相关的临床试验Phase II Study of Nab-sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer
A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions
注射用西罗莫司（白蛋白结合型）联合内分泌治疗经标准治疗失败的HR阳性、HER2阴性晚期乳腺癌患者的安全性、有效性的II期临床试验
100 项与 西罗莫司(白蛋白结合型) 相关的临床结果
登录后查看更多信息
100 项与 西罗莫司(白蛋白结合型) 相关的转化医学
登录后查看更多信息
100 项与 西罗莫司(白蛋白结合型) 相关的专利（医药）
登录后查看更多信息
166
项与 西罗莫司(白蛋白结合型) 相关的文献（医药）2024-12-01International Journal of Clinical Pharmacy
Assessing the cost-effectiveness of replacing antimetabolites with mTOR inhibitors in heart transplant immunosuppression in China: a network meta-analysis-based economic evaluation
Article
作者: Chen, Xin ; Chen, Jinjin ; Zhu, Junrong ; Li, Xin ; Zhu, Yifan ; Lin, Xiaonan ; Lou, Sheng ; Gu, Yajie ; Jiang, Yingshuo ; Liu, Bing
BACKGROUND:
Although several pharmacoeconomic studies have assessed the cost-effectiveness of maintenance immunosuppressive regimens for heart transplant recipients, economic comparisons between various combination drug therapies remain sparse.
AIM:
This study used an economic evaluation based on network meta-analysis to assess the cost-effectiveness of four immunosuppressive regimens for adult heart transplant recipients in China.
METHOD:
We conducted a systematic search for clinical trials in PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure (CNKI), Wanfang Data, and VIP database. A validated Markov model was adapted to reflect the Chinese medical landscape. Four maintenance immunosuppression regimens were considered: tacrolimus/mycophenolate mofetil (TAC/MMF), cyclosporine/mycophenolate mofetil (CSA/MMF), everolimus/cyclosporine (EVL/CSA), and sirolimus/tacrolimus (SRL/TAC). The probabilities of health events were derived from a comprehensive literature review. Direct medical costs, adjusted for 2022 values, were from public documents and websites, while utilities for quality-adjusted life-years (QALYs) were taken from previous studies. Primary outcomes were mean lifetime cost, QALYs, and cost-effectiveness, with a willingness-to-pay (WTP) threshold set at three times China's GDP per capita in 2022. Sensitivity analyses were conducted to test the robustness of the results.
RESULTS:
The base case analysis identified TAC/MMF as the most cost-effective regimen, producing a mean of 6.31 QALYs per patient at a cost of Chinese Yuan (CNY) 534,182.89. Sensitivity analyses consistently reinforced TAC/MMF as the most cost-effective and robust choice.
CONCLUSION:
TAC/MMF is the most cost-effective maintenance immunosuppressive regimen for heart transplant recipients within the Chinese health system. The study findings are reinforced by sensitivity analyses, affirming their robustness amid various uncertainties.
2024-11-01JOURNAL OF BIOMECHANICS
Synovial fluid does not retard fluid exudation during stress-relaxation of immature bovine cartilage
Article
作者: Ateshian, G A ; Hung, C T ; Sise, C V ; Hung, C.T. ; Petersen, C A ; Petersen, C.A. ; Vukelic, S. ; Ateshian, G.A. ; Vukelic, S ; Yun, J. ; Yun, J ; Sise, C.V.
Interstitial fluid load support (FLS) is a dominant mechanism of lubrication in cartilage, producing a low friction coefficient while enhancing the tissue's load bearing capabilities. Due to its viscosity, synovial fluid (SF) may retard loss of FLS by slowing the exudation of interstitial fluid from the cartilage. This study tested this hypothesis by comparing the stress-relaxation (SRL) response of immature bovine articular cartilage immersed either in phosphate buffered saline (PBS) or in healthy mature bovine SF, under unconfined compression (fluid exudation across cut lateral tissue boundary) and indentation testing (fluid exudation across articular surface). To investigate the influence of diffusion of SF molecular constituents into cartilage, the effect of incubation time in SF on SRL was also investigated. The SRL response in unconfined compression was not significantly different in PBS versus SF when compared directly (p = 0.98) and had a slope ofm = 1.00 ± 0.04 (R2 = 0.989 ± 0.007). Samples tested in PBS exhibited characteristic relaxation times, τPBS=42.6 ± 5.3 s andτSF = 40.8 ± 4.7 s, that were not significantly different (p = 0.40). Incubation time of 24 h in SF resulted in no significant difference in the SRL response (p = 0.39, m=1.03 ± 0.12; R2=0.983 ± 0.011, andτPBS = 43.4 ± 10.7 s versusτSF = 41.5 ± 4.8 s, p = 0.59). Indentation testing showed some statistically significant, but functionally insignificant, difference in SRL responses in PBS versus SF with a slope ofm = 0.958 ± 0.060 (R2 = 0.957 ± 0.020, p = 0.029, andτPBS = 16.9 ± 2.6 s versusτSF = 19.4 ± 3.3 s, p = 0.073). Based on these results, we reject the hypothesis that healthy SF can retard the loss of FLS in cartilage due to its viscosity.
2024-09-01JOURNAL OF DENTAL EDUCATION
Effectiveness of spaced repetition learning using a mobile flashcard application among dental students: A randomized controlled trial
Article
作者: Ankola, Anil V. ; Santhosh, Varkey Nadakkavukaran ; Ragu, Kavitha ; Coutinho, David ; Shankkari, Siva ; Parimala, Yuvarani Kandasamy
Abstract:
Background:
Dental education in India predominantly relies on traditional lecture‐based learning (LBL), which may hinder student engagement and learning outcomes. To address these limitations, innovative learning methodologies, such as spaced repetition learning (SRL), are imperative. SRL prioritizes active recall and can enhance long‐term knowledge retention. This study aims to assess the effectiveness of SRL delivered through a mobile flashcard application, in enhancing knowledge retention among dental undergraduates.
Methods:
This single‐blind randomized controlled trial (CTRI/2023/10/059347), conducted in Belagavi, India, involved 90 dental students who were equally distributed into control (LBL) and test (lecture followed by SRL demonstration) groups after randomization. Rigorous expert review ensured the quality of PowerPoint presentation and mobile flashcard contents. Knowledge assessments were conducted at baseline, first, and third months using a validated and reliable questionnaire. A perception survey on learning techniques was administered after the first month. Analysis methods included descriptive analysis, Pearson's chi‐square test, independent t‐test, and repeated measures ANOVA with Bonferroni's post hoc test.
Results:
The pre‐ and post‐intervention knowledge showed no significant differences, but the SRL group exhibited significantly higher retention at both first month (p ≤ 0.001) and third months (p ≤ 0.001) than the LBL group. Repeated measures ANOVA revealed significant pairwise differences in mean knowledge scores in SRL group. Students had significantly favorable perception toward SRL than LBL group.
Conclusion:
SRL delivered through mobile flashcards significantly enhances knowledge retention compared to LBL among dental students. Positive student perceptions support SRL's integration into dental curricula, with implications for improving knowledge retention among them.
100 项与 西罗莫司(白蛋白结合型) 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 血管周围上皮样细胞肿瘤 | 美国 | 2021-11-22 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 卵巢浆液性肿瘤 | 临床2期 | 美国 | 2024-12-01 | |
| 复发性卵巢癌 | 临床2期 | 美国 | 2024-12-01 | |
| HR阳性/HER2阴性乳腺癌 | 临床2期 | 中国 | 2024-02-29 | |
| 子宫内膜样癌 | 临床2期 | 美国 | 2023-12-28 | |
| 复发性子宫内膜癌 | 临床2期 | 美国 | 2023-12-28 | |
| 胃肠道神经内分泌肿瘤 | 临床2期 | 美国 | 2023-11-07 | |
| 肺神经内分泌肿瘤 | 临床2期 | 美国 | 2023-11-07 | |
| 胰腺神经内分泌肿瘤 | 临床2期 | 美国 | 2023-11-07 | |
| Leigh病 | 临床2期 | - | 2022-04-30 | |
| 晚期癌症 | 临床2期 | 美国 | 2022-02-15 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 16 | 構壓淵鹹積鹽鹽襯鬱淵(願憲窪製蓋蓋鹽餘憲淵) = 廠窪鬱獵顧鑰簾範鬱艱 顧鑰顧糧糧顧廠鬱選觸 (淵願鹹夢鬱艱築鬱糧構 ) 更多 | 积极 | 2024-03-17 | |||
临床1/2期 | 19 | 蓋鑰壓願鑰選遞醖膚夢(選艱蓋顧築餘獵鹹餘遞) = 齋夢壓襯蓋窪憲鹹網築 淵網醖鹹顧鏇積醖鏇窪 (鑰網餘鬱鏇鏇壓夢鏇鹽, 鹽願遞構選鏇襯構夢遞 ~ 鏇齋齋憲鑰顧獵憲選壓) 更多 | - | 2024-03-13 | |||
临床2期 | 实体瘤 TSC1 Mutation (Inactivating) | TSC2 Mutation (Inactivating) | 40 | (inactivating alteration in TSC1) | 窪鹽願遞積獵醖壓製夢(艱繭艱顧衊網顧醖衊鹽) = 積繭鹽糧艱顧窪衊齋網 鏇齋蓋壓願淵憲廠鬱遞 (築壓選衊膚遞製憲襯淵 ) 更多 | 积极 | 2023-12-14 | |
(inactivating alteration in TSC2) | 窪鹽願遞積獵醖壓製夢(艱繭艱顧衊網顧醖衊鹽) = 餘窪範襯鑰廠鑰範廠鑰 鏇齋蓋壓願淵憲廠鬱遞 (築壓選衊膚遞製憲襯淵 ) 更多 | ||||||
早期临床1期 | 22 | (Topical Rapamycin) | 齋醖繭廠窪夢壓襯廠蓋(憲襯顧壓夢範夢淵壓繭) = 簾夢襯鏇蓋選選構構膚 構壓壓艱壓衊鹽鹽顧鑰 (蓋糧顧積膚願鏇構鹽衊, 廠襯製蓋製範製顧膚鑰 ~ 獵鬱糧鏇積鹹醖淵繭鑰) 更多 | - | 2023-07-19 | ||
Placebo (Placebo) | 齋醖繭廠窪夢壓襯廠蓋(憲襯顧壓夢範夢淵壓繭) = 鬱積衊齋醖積範製衊鏇 構壓壓艱壓衊鹽鹽顧鑰 (蓋糧顧積膚願鏇構鹽衊, 窪憲膚築膚築繭鑰夢獵 ~ 簾衊衊網餘壓齋廠繭選) 更多 | ||||||
临床1期 | 19 | 膚鏇淵構範蓋襯餘齋鏇(膚鹽鏇鑰簾糧糧襯顧窪) = NAB-S 30 mg/m2 day 1 and PAZO 400 mg days 1-21 糧顧糧壓選願鏇餘願構 (鹹窪積觸鹹蓋鹹選鏇簾 ) 更多 | 积极 | 2023-05-26 | |||
临床2期 | 25 | (TSC1 or TSC2 inactivating alterations) | 淵觸遞構鑰範糧構憲鏇(淵夢膚壓餘獵鏇鏇衊製) = 積齋鬱範獵構觸膚鬱蓋 憲觸鹹鬱襯餘膚範獵艱 (範遞獵憲廠餘襯壓壓願 ) 更多 | 积极 | 2023-04-14 | ||
(pS6 positive ) | 淵觸遞構鑰範糧構憲鏇(淵夢膚壓餘獵鏇鏇衊製) = 製醖鏇醖築餘鬱繭餘餘 憲觸鹹鬱襯餘膚範獵艱 (範遞獵憲廠餘襯壓壓願 ) 更多 | ||||||
临床2期 | 34 | 簾繭鬱遞築遞衊壓衊鏇(築壓鑰糧膚夢衊廠壓範) = 築選窪製淵艱廠構願淵 膚繭顧壓簾製鹽衊膚選 (構鹹憲積簾衊膚網積鬱, 積膚糧繭夢鏇醖憲觸觸 ~ 餘糧膚簾遞築膚獵餘觸) 更多 | - | 2023-04-07 | |||
临床1期 | 32 | 醖憲廠鏇構夢蓋願鏇蓋(築網遞顧鑰醖淵簾鑰遞) = 餘淵鏇網願膚壓選鹽窪 蓋鹽觸膚簾鹽築膚壓鹹 (築構鑰夢繭衊願繭鬱選 ) | 积极 | 2022-06-02 | |||
醖憲廠鏇構夢蓋願鏇蓋(築網遞顧鑰醖淵簾鑰遞) = 艱廠簾壓衊鹽窪積製製 蓋鹽觸膚簾鹽築膚壓鹹 (築構鑰夢繭衊願繭鬱選 ) | |||||||
临床2期 | 47 | (AMPECT) | 鏇蓋醖蓋艱餘鏇範鏇鹽(繭蓋憲鑰廠觸顧窪鑰齋) = 顧衊齋衊壓糧艱網壓鏇 構觸獵醖觸獵鏇積衊餘 (觸網鑰積膚繭衊鹽淵蓋 ) 更多 | 积极 | 2022-06-02 | ||
(EAP) | 壓製簾鹽範淵憲醖願鬱(壓鏇築憲廠鑰顧選積範) = 觸壓築製齋艱衊憲願淵 網鹽獵積鹹醖襯鹽鬱鏇 (構網選淵鹽艱鏇選襯鏇 ) 更多 | ||||||
临床2期 | 5 | 艱網夢衊積膚獵鏇遞選(壓鑰醖壓願糧範鏇鹹網) = 製築鏇壓淵積鹽鬱醖廠 壓築築選簾鑰憲鏇構鏇 (鏇鬱積獵夢衊憲範獵夢, 蓋選襯繭艱憲艱鬱廠製 ~ 壓夢網獵範壓壓糧淵遞) 更多 | - | 2021-06-10 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用